TriangleHEALTH PROFESSIONAL · SOURCE READING
Interferon Alfa
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for CML
Long-term data are also available for patients treated with interferon alfa.[8-10] Approximately 10% to 20% of these patients have a complete cytogenetic response with no evidence of BCR::ABL1 translocation by any available test, and most of these patients are disease free beyond 10 years. Maintenance therapy with interferon is required, however, and some patients experience side effects that preclude continued treatment.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice